MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5694/mja17.00937

Медицинская библиотека · The Medical journal of Australia · 2018

Relative survival of patients with lymphoma in Queensland according to histological subtype.

Wright Fraser, Hapgood Greg, Loganathan Aravi, Dunn Nathan, Philpot Shoni, Moore Julie, Mollee Peter

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To evaluate relative survival of patients in Queensland with different lymphoma subtypes; to determine whether outcomes have improved with recent changes in treatment; to evaluate relative survival according to place of residence and socio-economic status.

DESIGN

Retrospective population-based study; analysis of data from the Oncology Analysis System, an online reporting tool for cancer incidence and outcomes in Queensland.

PARTICIPANTS

Patients over 15 years of age diagnosed with lymphoma in Queensland during 1993-2012.

MAIN OUTCOME MEASURES: Relative survival by lymphoma subtype; influence of place of residence and socio-economic status, age group, sex, year of diagnosis (in 5-year bands), and Pharmaceutical Benefits Scheme funding of rituximab for treating B-cell lymphomas on relative survival.

RESULTS

9509 people (56% men) were diagnosed with lymphoma during 1993-2012. Five-year relative survival improved significantly between 1993-1997 and 2008-2012 for patients with diffuse large B-cell lymphoma (47%; 95% CI, 42-51% v 64%; 95% CI, 61-67%) or follicular lymphoma (62%; 95% CI, 57-66% v 88%; 95% CI, 85-90%; each P < 0.001). Rituximab became available for treating these subtypes during 2003-2006. There was no change in relative survival for patients with Hodgkin lymphoma (81%; 95% CI, 76-85% v 80%; 95% CI, 75-84%; P = 0.22). The only statistically significant difference according to place of residence or socio-economic status was inferior relative survival for rural residents with diffuse large B-cell lymphoma (hazard ratio, 1.14; 95% CI, 1.01-1.28).

CONCLUSION

Relative survival for patients with B-cell non-Hodgkin lymphoma improved significantly with the introduction of rituximab as first-line therapy in Australia.

Для цитирования: Wright Fraser, Hapgood Greg, Loganathan Aravi, Dunn Nathan, Philpot Shoni, Moore Julie, Mollee Peter. Relative survival of patients with lymphoma in Queensland according to histological subtype.. The Medical journal of Australia. 2018. DOI: 10.5694/mja17.00937.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.